Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (2205)	2/11/2008 9:54:39 AM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

ANX is trying again to go over the resistance at the ).50 level.<g> The stock is up around 7.90% on low volume. bigcharts.marketwatch.com ANX has announced that it has completed a marketing-enabling bioequivalence study of its ANX-530. The primary endpoint in the study was met, with pharmacokinetic equivalence observed between ANX-530 & Navelbine, with significant reduction in injection site reactions. It plans to file an NDA in the 4thQ. It will be presenting the results of ANX-530 at the AACR meeting in San Diego in April. ANX doesn't have significant LTD, the insiders reportedly hold > 15%; the short ratio went up around 13% & is about 2x its ADV. Will see if the stock can get back to the $1 level.<g> bigcharts.marketwatch.com Bernard